<DOC>
	<DOCNO>NCT01955304</DOCNO>
	<brief_summary>This study determine effect food pharmacokinetics ( PK ) single dose 4mg fruquintinib normal healthy subject .</brief_summary>
	<brief_title>Food Effect Study Single Dose Fruquintinib ( HMPL-013 ) Healthy Subjects</brief_title>
	<detailed_description>This study open-label , randomize , two-period , crossover PK food effect study fruquintinib administer orally 4mg . Subjects screen eligibility 14 day prior entry study . For 2 study period , subject admit clinical research unit ( CRU ) day dose fast overnight ( approximately 10 hour ) . On morning dose 2 study period , subject receive single oral dose 4 mg fruquintinib either fast fed state . Subjects remain CRU least 120 hour administration study drug collection serial blood sample pharmacokinetic ( PK ) analysis safety monitoring . Subjects return CRU safety assessment 336 hour postdose .</detailed_description>
	<criteria>Males , 18 45 year age , inclusive . Body mass index ( BMI ) within range 19 25 kg/m2 , inclusive . In good health , determine clinically significant finding medical history , physical examination , 12lead ECG , vital sign . Adequate hepatic , renal , heart , hematologic function Male subject either sterile agree use , period inform consent 90 day follow Study Completion , 1 follow approve method contraception : double barrier method ( eg , male condom spermicide , use female sexual partner intrauterine device spermicide , female condom spermicide , contraceptive sponge spermicide , diaphragm spermicide , use cervical cap spermicide ) ; sterile sexual partner ; female sexual partner use intravaginal system ( eg , NuvaRing® ) ; partner use oral , implantable , transdermal , injectable contraceptive . Able comprehend willing sign inform consent form ( ICF ) . Significant history clinical manifestation significant metabolic/endocrine , allergic , dermatological , hepatic , renal , hematological , pulmonary , immune , cardiovascular , gastrointestinal , genitourinary , neurological , psychiatric disorder ( determined Investigator ) . History significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator . History stomach intestinal surgery , nephrectomy , cholecystectomy resection would potentially alter absorption and/or excretion orally administer drug determine investigator ( appendectomy and/or hernia repair may allow ) . History presence abnormal ECG , , Investigator 's opinion , clinically significant . Diagnosis alcoholism drug addiction within 1 year prior Period 1 Checkin . Participation investigational drug study receipt investigational study drug occur within 5 halflives 30 day , whichever long prior inform consent . Use prescription medication product within 14 day prior Period 1 prior inform consent . Use overthecounter ( OTC ) , nonprescription preparation ( include vitamin , mineral , phytotherapeutic , herbal , dietary supplement , plant derive preparation ) within 7 day prior study period Checkin . Use alcohol , grapefruit , Seville orange , caffeinecontaining food , juice , beverage within 72 hour prior study period Checkin . Use known hepatic renal clearance alter agent ( eg , erythromycin , cimetidine , barbiturate , phenothiazine , herbal/plant derive preparation St. John 's Wort , etc . ) period 60 day prior informed consent ; Poor peripheral venous access . Donation blood ≥ 250 mL 30 day prior inform consent study completion , inclusive , plasma 2 week prior inform consent study completion , inclusive . Receipt blood product within 2 month prior Period 1 Checkin ; Blood pressure great 140/90 mmHg confirm repeat Screening Period 1 Checkin . Any acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>